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A. Delivery of high concentrations of drug into the bladder
B. A lower incidence of systemic side effects
C. Repair of injured bladder urothelium with liposomes
D. All of the above
Urol Sci 2015;26(1):3e6
2. Which one of the following is not an advantage of
liposomeenano-approaches for intravesical drug delivery?
A. Able to modulate the release and absorption of instilled
drugs coupling in liposomes
B. Can incorporate various sizes of drug molecules, both hy-
drophilic and hydrophobic
C. There is greater uptake into cells via phagocytosis
D. The nontoxic nature of the lipids
Urol Sci 2015;26(1):3e6
3. What are the possible mechanisms of action of liposomes on the
urothelium?
A. Protects the urothelium from penetration by irritants
B. Alters the muscarinic receptors in the urotheliumhttp://dx.doi.org/10.1016/S1879-5226(15)00051-2
1879-5226C. Stabilization of the neuromembranes of damaged nerves
D. Reduction of nerve hyperexcitability
Urol Sci 2015;26(1):3e6
4. Which of the following statements of overactive bladder (OAB)
syndrome in men is incorrect?
A. Antimuscarinic therapy alone cannot improve OAB symp-
toms in men with bladder outlet obstruction (BOO)
B. Diagnosis of OAB in male patients with lower urinary tract
symptoms (LUTS) should be based on the symptom of ur-
gency with/without urgency incontinence
C. The grade of urgency should be carefully evaluated and BOO,
neurogenic lesion as well as cognitive function should be
carefully assessed before making a ﬁnal diagnosis of idio-
pathic OAB
D. In men with benign prostatic hyperplasia and OAB symp-
toms, OAB is usually secondary to BOO
Urol Sci 2015;26(1):7e16
CME Test / Urological Science 26 (2015) IeIIII5. Which of the following statements of male LUTS is incorrect?
A. Male LUTS may originate from bladder dysfunction or
bladder outlet disorders
B. Detrusor overactivity and urethral sphincter dysfunction
should be considered in young men with LUTS or small
prostate
C. Urodynamic testing is indicated especially when male pa-
tients with LUTS are ready to undergo invasive therapy for
LUTS, such as transurethral resection of the prostate or laser
prostatectomy
D. First-line treatment of OAB is always antimuscarinic agents
Urol Sci 2015;26(1):7e16
6. Which of the following statements about medical treatment for
OAB and male LUTS is incorrect?
A. Antimuscarinics or beta-3-adrenoceptor agonist is recom-
mended for men with LUTS suggestive of OAB and without
evidence of BOO
B. Men with both voiding and storage LUTS are recommended
to take alpha-blocker with/without 5-alpha-reductase in-
hibitor ﬁrst, followed by antimuscarinics or beta-3-
adrenoceptor agonist
C. Botulinum toxin A 100U is recommended in patients with
refractory OAB, excluding patients with BOO
D. Aging patients with medical comorbidity or a post-void re-
sidual > 100 mL do not have increased risks of urinary
retention or urinary tract infection




C. Urinary tract infection
D. Dry mouth
Urol Sci 2015;26(1):17e23
8. Which one of the following is not a possible mechanism of
mirabegron?
A. Direct relaxation of detrusor smooth muscle
B. Activation of adenylyl cyclase
C. Increase in phospholipase C
D. Increase in intracellular levels of cyclic adenosine phosphate
(cAMP)
Urol Sci 2015;26(1):17e23
9. Which one of the following is not a clinical beneﬁt of
mirabegron?
A. Decreasing the frequency of micturition
B. Decreasing the frequency of stress urinary incontinence
episodes
C. Decreasing the frequency of urinary incontinence episodes
D. Improving quality of life
Urol Sci 2015;26(1):17e23
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Answers:
1. (C) 2. (D) 3. (A) 4. (A) 5. (D) 6. (C)
